A Phase 1, Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (AG 221, CC 90007) in Subjects With Moderate and Severe Hepatic Impairment.
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Enasidenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.
- 26 Sep 2017 New trial record